One-Stop Oncolytic Bacterial Therapy Development and In Vivo Evaluation Capabilities at Alfa Cytology
New York, USA - March 2, 2026 - With the development of tumor immunotherapy, oncolytic bacterial therapy has gradually become an important direction of cancer treatment research. The therapy uses engineered or attenuated bacteria to target the tumor microenvironment and exert antitumor effects by lysing tumor cells and activating the host immune response. To support the development of candidate oncolytic bacterial therapies, Alfa Cytology has constructed an integrated one-stop oncolytic bacterial therapy development platform. This platform is complemented by a professional in vivo pharmacodynamic evaluation laboratory research support system.
The research and development of oncolytic bacterial therapy involves many key links, such as strain screening, genetic engineering, functional verification, and preclinical efficacy evaluation. Relying on the OncoBact™ precision oncolytic bacteria technology platform, Alfa Cytology integrates research and development resources to support the research team in completing the systematic research process from strain screening to in vivo efficacy verification.
In the one-stop oncolytic bacterial therapy development platform, Alfa Cytology supports candidate strain development through strain screening and bacterial genetic engineering. With the help of synthetic biology and gene editing technology, researchers can design bacterial vectors that can respond to the characteristics of the tumor microenvironment and achieve selective proliferation of tumor tissues. At the same time, the platform supports multimodal therapeutic payload delivery research and regulates bacterial survival and clearance through biosafety control strategies.
Based on in vivo functional verification, Alfa Cytology further established an in vivo pharmacodynamic evaluation laboratory. This laboratory systematically analyzes the tumor-targeting ability, therapeutic effect, and biological safety of oncolytic bacteria. It provides key data support for preclinical research.
Through this laboratory, Alfa Cytology can construct orthotopic, metastasis, PDX, and drug-resistant tumor models. It also conducts tumor growth monitoring, metastasis inhibition evaluation, tumor microenvironment analysis, and bacterial distribution studies in vivo. These experiments provide an experimental basis for optimizing treatment strategies. Additionally, the platform supports research on combination therapy strategies, offering more pathways for treating complex tumors.
"Preclinical validation data will be important to assess the feasibility of treatment strategies," said a spokesperson for Alfa Cytology. "By integrating the one-stop oncolytic bacterial therapy development system with in vivo pharmacodynamic evaluation laboratory services, we are committed to supporting research into innovative oncolytic bacterial therapies."
About Alfa Cytology
Alfa Cytology specializes in preclinical research supporting cancer immunotherapy and innovative cancer treatment strategies. Alfa Cytology is committed to providing systematic early-stage development solutions to research institutions, biotechnology companies, and related research organizations. By integrating advanced experimental techniques, animal model resources, and professional research teams, Alfa Cytology provides experimental systems and technical support for a variety of emerging anti-tumor technologies to help scientific research teams promote the process of preclinical research.
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
